Logo

Evotec Expands its 2016 Agreement with Bristol-Myers Squibb

Share this

Evotec Expands its 2016 Agreement with Bristol-Myers Squibb

Shots:

  • Evotec to receive $6M payment from BMS to expand its partnership with the inclusion of additional cell lines
  • In 2016- Evotec signed a 5-year research agreement with Celgene (now a part of BMS) for the identification of therapies based on Evotec’s technology platforms in conjunction with the human iPSC- based platform for multiple neurodegenerative diseases
  •  iPSCs are adult cells genetically reprogrammed to an embryonic stem cell for expressing genes & properties of embryonic stem cells

Click here to read full press release/ article | Ref: Evotec | Image: Behance


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions